Quebec City, June 7, 2011 – TSO3 Inc. (“TSO3”) (TSX: TOS), an innovator in sterilization technology for medical devices in healthcare settings, today announced that it has begun to support 3M™ commercialization efforts by shipping new 3M™ Optreoz™ 125-Z sterilizers for installation at customer locations.
“Months of collaboration with our channel partner are now showing tangible results”, said R.M. (Ric) Rumble, President and CEO of TSO3. “We are beginning to ship units from our backlog and have additional shipments planned for next month and beyond. Our efforts are now in direct support of our channel partner’s phased introduction of the new technology, as was previously outlined during our Annual General Meeting of Shareholders (AGM)”, Mr. Rumble concluded.
As part of the recent AGM held on May 11, 2011, information was shared by TSO3 including examples of launch materials provided by 3M™ regarding their approach to launching the 3M™ Optreoz™ 125-Z Sterilizer. This material includes product positioning to customers and launch sequences in more than a dozen countries, as well a communications strategy, examples of print literature and E-tools. The webcast of this event and the PowerPoint presentation will be archived for a period of 90 days and are available at http://www.cnw.ca/en/webcast/viewEvent.cgi?eventID=3474900
TSO3, founded in Québec City in 1998, specializes in the research and development of innovative, high-performance medical instrument sterilization technology with high commercial potential. TSO3 designs products for sterile processing areas in the hospital environment and offers an advantageous replacement solution to other low temperature sterilization processes currently used in hospitals.
The statements in this release and oral statements made by representatives of TSO3 relating to matters that are not historical facts (including, without limitation, those regarding the timing or outcome of any financing undertaken by TSO3) are forward-looking statements that involve certain risks, uncertainties and hypotheses, including, but not limited to, general business and economic conditions, the condition of the financial markets, the ability of TSO3 to obtain financing on favourable terms and other risks and uncertainties.
The TSX has neither approved nor disapproved the information contained herein and accepts no responsibility for it.
-30-Back to Posts